Which startups have raised the most funding in the longevity market?

Last updated: 13 March 2026

Download our beautiful pitch about the longevity market

market research pitch 2026 statistics longevity market

In our longevity market deck, you will find everything you need to understand the market

The longevity market has attracted over $13 billion in venture funding, with startups working on everything from cellular reprogramming to consumer health diagnostics.

Below is a ranked list of the top funded longevity startups, built from verified public sources and updated every month to keep the data fresh.

Whether you are an investor scouting deals, a founder benchmarking your raise, or a researcher tracking where capital flows in aging science, this page is your reference.

And if you want to better understand this new industry, you can download our pitch covering the longevity market.

A quick summary table

Metric Value
Most funded longevity startup Altos Labs ($3.0B)
Second most funded longevity startup Oura / Retro Biosciences (tied at $1.2B)
Largest single longevity funding round Retro Biosciences ($1.0B, Series A)
Median funding across longevity startups ~$24M
Share of funding captured by the top 10 ~67%
Median time since last round ~17 months
Longevity startups that raised in the last 12 months 35 out of 94
Total capital deployed in longevity startups ~$13.1B
Longevity startups with IPO or acquisition exit 8 (4 IPOs, 4 acquired)
Most active longevity investor by portfolio count Khosla Ventures (6+ companies)
chart VC fundraising startup years longevity market

In our longevity market deck, we show you long-term trends so you can make better decisions

Top startups in the longevity market ranked by total funding raised

Here is an updated table that ranks the top startups in the longevity market based on the total amount of funding they have raised to date.

The table also includes the total number of funding rounds, the date and size of the latest round, the financing type (e.g. Series A, equity financing), key investors, the startup's current status (active, IPO, acquired, or shut down), and a confidence score based on the data collected (we excluded startups with very low data confidence, to make sure everything is reliable).

If you're interested in knowing how much these startups are worth, you can check our list of the top startups in the longevity market ranked by valuation.

# Startup What They Do Total Raised ($) Total Rounds Last Round Date Last Round Amount ($) Last Round Type Key Investors Current Stage Confidence
1 Altos Labs Cellular rejuvenation therapeutics $3.0B 1 January 2022 $3.0B Initial financing ARCH Venture Partners, Jeff Bezos, Yuri Milner Active Strong
2 Oura Smart health-tracking ring platform $1.2B 9 October 2025 $900M Series E Fidelity, ICONIQ, Whale Rock Active Partial
3 Retro Biosciences Longevity therapeutics for age reversal $1.2B 2 January 2025 $1.0B Series A Sam Altman Active Strong
4 BioSplice Therapeutics Alternative-splicing therapeutics for diseases $778M 3 April 2021 $120M Equity financing Eventide Asset Management, aMoon, SymBiosis II Active Strong
5 Insilico Medicine AI-driven drug discovery platform $688M 6 December 2025 $293M IPO Warburg Pincus, Qiming Venture Partners IPO Strong
6 BioAge Labs Aging-targeted obesity therapeutics $491M 5 September 2024 $198M IPO Sofinnova, RA Capital, Andreessen Horowitz IPO Strong
7 Celularity Placenta-derived cell therapies $396M 4 October 2025 $2M Private Placement Celgene, Starr Insurance, Dragasac Limited IPO Partial
8 Human Longevity Precision longevity clinics and diagnostics $380M 5 August 2024 $40M Series B TVM Capital Healthcare, Panacea Venture, Emerging Technology Partners Active Partial
9 Function Health Preventive diagnostics and health platform $351M 2 November 2025 $298M Series B Redpoint Ventures, Andreessen Horowitz, Aglaé Ventures Active Strong
10 Neko Health Preventive body-scan health centers $325M 2 January 2025 $260M Series B Lightspeed Venture Partners, General Catalyst, Lakestar Active Full
11 Juvenescence Longevity drug development platform $283M 5 May 2025 $76M Series B-1 M42, Grok Ventures, IPGL Active Partial
12 NewLimit Epigenetic reprogramming medicines $280M 3 May 2025 $130M Series B Kleiner Perkins, Khosla Ventures, NFDG Active Full
13 Viome Life Sciences Microbiome diagnostics and nutrition $243M 6 September 2024 $25M Series D Khosla Ventures, Bold Capital, WRG Ventures Active Full
14 Loyal Longevity drugs for dogs $205M 5 February 2026 $100M Series C age1, Baillie Gifford Active Partial
15 Unity Biotechnology Senolytic drugs for aging diseases $200M 4 March 2018 $55M Series C EcoR1 Capital, 6 Dimensions Capital, ARCH Venture Partners Shutdown Full
16 Cambrian Bio Builds healthspan therapeutics platform $188M 4 June 2023 $23M Later-stage private round Anthos Capital, Apeiron Investment Group Active Partial
17 resTORbio mTOR inhibitors for aging diseases $163M 3 January 2018 $98M IPO PureTech Health, OrbiMed Acquired Full
18 Alzheon Alzheimer's oral therapeutics developer $160M 3 June 2024 $100M Series E Alerce Medical Technology Partners Active Partial
19 Life Biosciences Aging-related disease therapeutics $157M 3 January 2022 $82M Series C Alpha Wave Ventures Active Strong
20 SciNeuro Pharmaceuticals Neurodegenerative disease therapeutics $153M 2 December 2025 $53M Equity Financing LAV, ARCH Venture Partners Active Full
21 Aeovian Pharmaceuticals Selective mTORC1 small molecules $142M 3 December 2025 $55M Series B Luma Group, CTI Life Sciences Fund, Foresite Capital Active Full
22 Nura Bio Neuroprotective small-molecule biotech $141M 2 September 2024 $68M Series A extension The Column Group, Samsara BioCapital, Sanofi Ventures Active Full
23 Fountain Life Longevity clinics and diagnostics $113M 3 August 2025 $18M Series B EOS Ventures, Todd Wanek, B.K. Modi Active Partial
24 Nuritas AI-discovered bioactive peptide ingredients $110M 4 December 2024 $42M Series C M&G Investments, McWin Capital Partners, Grosvenor Active Full
25 L-Nutra Longevity nutrition and fasting products $84M 3 January 2026 $37M Series D Mubadala, Brentwood Associates, Stéphane Bancel Active Partial
26 Corsera Health Cardiovascular prediction and prevention biotech $80M 1 January 2026 $80M Series A Forbion, Population Health Partners, John Maraganore Active Full
27 Rejuveron Life Sciences Longevity therapeutics platform $76M 2 September 2023 $75M Series B Catalio Capital, Apeiron Investment Group, Mubadala Capital Active Partial
28 Timeline Longevity supplements and skin health $75M 2 January 2024 $66M Series D BOLD (L'Oréal), Nestlé Active Strong
29 CohBar Mitochondria-based therapeutics for aging $65M 6 November 2021 $15M Public offering Public-market investors Shutdown Partial
30 Illimis Therapeutics Neuroinflammation fusion-protein therapeutics $64M 3 July 2025 $42M Series B DSC Investment, Woori Venture Partners, Korea Development Bank Active Partial
31 Elevian Regenerative medicines for aging $61M 3 September 2021 $40M Series A Prime Movers Lab, Bold Capital Partners, Leslie Ventures Active Full
32 Blueprint Consumer longevity products platform $60M 1 October 2025 $60M Angel / Venture Round Naval Ravikant, Balaji Srinivasan, Winklevoss brothers Active Partial
33 Gordian Biotechnology In vivo screening for aging therapies $60M 1 April 2025 Undisclosed Venture equity The Longevity Fund, Founders Fund, Gigafund Active Low
34 Elysium Health Consumer longevity health products $60M 2 December 2019 $40M Series C GISEV Family Office, Mayo Clinic Ventures, General Catalyst Active Low
35 Liom Non-invasive biomarker wearable $59M 3 December 2025 $16M Series A extension Ornament Health, Geberit, Red Bull Ventures Active Partial
36 Neurable Brain-computer interface consumer tech $56M 4 December 2025 $35M Series A Pace Ventures, M Ventures, Ultratech Capital Partners Active Strong
37 Biograph Preventive longevity diagnostics clinics $54M 2 February 2025 Undisclosed Seed VC Vy Capital, Human Capital, WndrCo Active Low
38 Rubedo Life Sciences Senolytic therapies for aging diseases $52M 2 April 2024 $40M Series A Khosla Ventures, Ahren Innovation Capital, LongeVC Active Full
39 Arda Therapeutics Targeted cell depletion therapies $43M 1 October 2024 $43M Series A a16z, Two Sigma Ventures, GV Active Full
40 Alkahest Plasma-based aging therapeutics $41M 2 March 2015 $38M Series A Grifols Acquired Strong
41 Cellular Origins Cell therapy manufacturing automation $40M 1 December 2025 $40M Series A Johnson & Johnson Innovation, Highland Europe, BGF Active Full
42 LyGenesis Organ regeneration using lymph nodes $40M 3 October 2024 $18M Series A extension Prime Movers Lab, Juvenescence Active Partial
43 Neuraly Neurodegenerative disease therapeutics $36M 2 July 2018 $36M Series A D&D Pharmatech, Smilegate Investment, InterVest Active Partial
44 Jocasta Neuroscience Klotho therapies for cognition $35M 1 August 2025 $35M Series A True Ventures, Moore Strategic Ventures, SC8 Investments Active Full
45 Amplifier Therapeutics AMPK drugs for aging diseases $33M 1 October 2023 $33M Series A Cambrian Bio, RA Capital, Future Ventures Active Strong
46 Turn Biotechnologies mRNA epigenetic reprogramming therapies $29M 2 September 2023 $29M Series A Khosla Ventures, Formic Ventures, Shanda Group Active Low
47 Oisin Biotechnologies Genetic medicines for age-related disease $25M 3 July 2024 $15M Series A AbbVie Ventures, Kizoo, Qiming Venture Partners USA Active Partial
48 Cyclarity Therapeutics Oxysterol-targeting age-related therapeutics $24M 4 December 2024 $6M Series A tranche 1 Not fully disclosed Active Full
49 MindImmune Therapeutics Neuroinflammation drugs for Alzheimer's $24M 4 November 2025 $10M Series A extension Dolby Family Ventures, Pfizer Ventures, Gates Frontier Active Partial
50 Tolerance Bio Thymus-based immune therapies $20M 2 December 2024 $3M Seed extension Pacific 8 Ventures, Columbus Venture Partners, Criteria Bio Ventures Active Full
51 Junevity siRNA cell-reprogramming therapeutics $20M 2 December 2025 $10M Seed Extension Goldcrest Capital, Godfrey Capital Active Full
52 Modulo Bio Neuroimmune drugs for neurodegeneration $19M 3 March 2025 $5M Strategic investment ADDF, Initialized Capital, Cantos Active Strong
53 Shift Bioscience AI-driven cell rejuvenation discovery $18M 1 October 2024 $16M Seed BGF, F-Prime Capital, Kindred Capital Active Low
54 Longevica Longevity therapeutics and supplements $16M 2 November 2021 $3M Venture round Xploration Capital Acquired Partial
55 Generation Lab Biological age diagnostics $15M 2 October 2025 $11M Seed Accel, Samsung Next, Zone2 Active Partial
56 Booster Therapeutics Proteasome activator medicines $15M 1 October 2024 $15M Seed Apollo Health Ventures, Novo Holdings Active Full
57 Rejuvenate Bio Gene therapies for age-related disease $15M 1 April 2021 $15M Series A Kendall Capital Partners, VCapital, Digitalis Ventures Active Strong
58 Grey Matter Neurosciences Ultrasound therapies for brain aging $14M 1 January 2025 $14M Seed Wittington Innovation Fund, TIAP, Ontario Brain Institute Active Full
59 Edifice Health Inflammation and immune-age diagnostics $14M 1 April 2021 $14M Series A Leaps by Bayer, Paladin Capital, Vertical Venture Partners Active Strong
60 Morphoceuticals Bioelectric regenerative medicine platform $13M 2 September 2024 $4M Seed Prime Movers Lab, Juvenescence Active Strong
61 Radar Therapeutics RNA-sensing programmable medicines $13M 1 May 2024 $13M Seed NFX Bio, Eli Lilly, Biovision Ventures Active Full
62 Amphix Bio Peptide therapeutics for regeneration $13M 1 December 2025 $13M Seed Not publicly disclosed Active Partial
63 MitoRx Therapeutics Mitochondrial-targeted obesity therapeutics $12M 3 November 2025 $7M Pre-Series A Oshen Holdings, Wren Capital, UKI2S Active Strong
64 Circulate Health Therapeutic plasma exchange longevity $12M 1 July 2025 $12M Seed Khosla Ventures, Seaside Ventures, CSC Ventures Active Full
65 Everlab AI preventive longevity healthcare $12M 2 July 2025 $10M Seed Left Lane Capital, AfterWork Ventures Active Full
66 Acorn Biolabs Cell preservation for regenerative medicine $12M 3 May 2024 $8M Series A Merz Aesthetics, TELUS Global Ventures, MDE Investments Active Strong
67 Epiterna Longevity therapeutics for pets and humans $11M 1 August 2023 $11M Seed Prima Materia Active Full
68 Rejuvenation Technologies mRNA telomere-lengthening therapeutics $11M 1 September 2023 $11M Seed Khosla Ventures, Shanda Ventures, Asymmetry Ventures Active Full
69 Cirrus Therapeutics Ocular gene and cell therapies $11M 1 October 2025 $11M Seed ClavystBio, Polaris Partners, SEEDS Active Full
70 Vasa Therapeutics Cardiovascular aging therapeutics $11M 2 March 2024 $5M Seed extension Orphinic Scientific, i&i Biotech Fund I SCSp Active Strong
71 Repair Biotechnologies Cholesterol-clearing aging therapeutics $11M 3 June 2023 $9M Series A Undisclosed Active Partial
72 Tally Health Consumer longevity testing and supplements $10M 1 April 2023 $10M Seed Forerunner Ventures, L Catterton, G9 Ventures Active Full
73 NaNotics Subtractive nanoparticles for disease $10M 2 October 2023 Undisclosed Series A LifeSpan Vision Ventures Active Low
74 clock.bio Rejuvenation biology drug discovery $9M 2 October 2024 $5M Seed LocalGlobe, BlueYard Capital, Onsight Ventures Active Partial
75 Biopeak AI-driven longevity clinics $8M 3 January 2026 $3M Follow-on venture round NKSquared, Prashanth Prakash, Claypond Capital Active Partial
76 Gero AI aging drug discovery $8M 3 October 2023 $6M Series A extension Melnichek Investments, Bulba Ventures Active Partial
77 SENISCA RNA-based senotherapeutics $7M 2 March 2024 $5M Seed Emerging Longevity Ventures, QantX, Lifespan Vision Ventures Active Strong
78 Thymmune Therapeutics Thymic cell immune therapies $7M 1 March 2023 $7M Seed Pillar VC, NYBC Ventures, George Church Active Strong
79 Cyclana Bio Women's health tissue therapeutics $7M 1 October 2025 $7M Pre-Seed NFX, Eka Ventures, Cocoa VC Active Full
80 Matter Bio Genome integrity longevity therapeutics $7M 2 May 2024 $7M Seed LifeSpan Vision Ventures, quadraScope Ventures Active Partial
81 Genflow Biosciences Gene therapies for longevity $6M 3 March 2025 $1M Post-IPO equity investment Premier Miton IPO Strong
82 Tomorrow Bio Human cryonics and biostasis $6M 1 May 2025 $6M Seed Blast.Club, Truventuro Active Strong
83 Biolytica AI longevity data platform $6M 1 May 2023 $6M Seed Maximon Active Full
84 Deciduous Therapeutics Senescent-cell clearing immunotherapies $6M 5 October 2023 Undisclosed Venture equity LifeSpan Vision Ventures Active Low
85 GlycanAge Glycan-based biological age testing $4M 1 February 2024 $4M Seed LAUNCHub Ventures, Kadmos Capital Active Full
86 NADMED NAD metabolite diagnostic testing $4M 2 August 2024 $4M Series A Nordic Science Investments, Voima Ventures, University of Helsinki Funds Active Full
87 AgelessRx Longevity telehealth prescriptions platform $4M 2 November 2022 Undisclosed Undisclosed equity round Joshua Rosenthal, Pareto Holdings Active Partial
88 Mito Health AI preventive health platform $4M 3 March 2025 $2M Seed Y Combinator, Capital X, XA Network Active Partial
89 NOVOS Longevity nutraceuticals and testing $3M 2 March 2026 Undisclosed Strategic minority investment Unilever Ventures Active Partial
90 Bionic Health AI-powered preventive care clinic $3M 1 March 2023 $3M Seed IDEA Fund Partners, Studio VC, Alumni Ventures Acquired Full
91 Decode Age Longevity tests and supplements $2M 3 December 2025 $2M Pre-Series A Krishna Prasad Chigurupati, IVY Growth Associates Active Low
92 ImmuneAGE Bio Immune-system rejuvenation platform $2M 1 July 2024 $2M Seed Balaji Srinivasan, Thomas Ebeling Active Partial
93 Leucadia Therapeutics Alzheimer's device-based therapy $2M 1 2017 $2M Seed Methuselah Fund, Bioverge Ventures, Wasabi Ventures Active Low
94 LinkGevity Anti-necrotic longevity drug discovery <$1M 1 January 2025 <$1M Accelerator / Pre-Seed KQ Labs, Francis Crick Institute Active Partial
market map chart top companies startups longevity market

In our longevity market deck, we will give you useful market maps and grids

Key funding trends in the longevity market

Insights

  • Altos Labs' $3.0B single round exceeds the combined funding of Retro Biosciences and BioSplice Therapeutics ($2.0B together), making cellular reprogramming the most capital-intensive bet in longevity therapeutics.
  • Function Health's $298M Series B is the largest disclosed venture round among private longevity startups, a signal that investors see consumer-scale potential in preventive lab-testing platforms beyond traditional biotech drug pipelines.
  • Khosla Ventures appears in at least six longevity portfolios (including Circulate Health, Rubedo Life Sciences, Rejuvenation Technologies, Viome, and NewLimit), making the firm arguably the most prolific dedicated longevity market investor.
  • Consumer-facing longevity platforms (Neko Health, Function Health, Viome, Tally Health, Acorn Biolabs) collectively raised over $700M, showing that longevity funding now extends well beyond drug pipelines into diagnostics, wearables, and supplements.
  • Retro Biosciences ($1.2B) and NewLimit ($280M), backed respectively by Sam Altman and Coinbase co-founder Brian Armstrong, together account for $1.5B and illustrate how tech-founder conviction capital is reshaping the scale of longevity funding.
  • Unity Biotechnology raised $200M through Series C before shutting down, a quantitative reminder that substantial early funding does not guarantee clinical or commercial success in the senolytics space.
  • Booster Therapeutics ($15M seed from Apollo Health Ventures and Novo Holdings) and Radar Therapeutics ($13M seed with Eli Lilly participation) show large pharma-adjacent investors actively seeding early-stage longevity platforms at competitive round sizes.
  • Corsera Health raised $80M in a single Series A (the largest disclosed Series A for cardiovascular aging), suggesting that cardiometabolic longevity is now attracting conviction-sized first rounds from specialist biotech investors.
  • Cellular Origins' $40M Series A for cell therapy manufacturing automation, backed by J&J Innovation, signals that longevity market investors value manufacturing infrastructure alongside therapeutic pipelines.
longevity trend chart

In our longevity market deck, we have collected signals proving this market is hot right now

A few word about our methodology

As you can see, we built a database that ranks startups in the longevity market based on their total cumulative fundraising. To create this ranking, we reviewed many sources and cross-checked information across multiple places.

Whenever possible, we prioritized official company communications, since they are the most reliable source for funding amounts. When those were not available, we relied on reputable industry sources such as TechCrunch, Crunchbase, Financial Times or Forbes (to name a few).

We excluded random blogs, unverified websites, and any sources that could not be validated.

When funding rounds were announced in other currencies such as euros, Swiss francs, Singapore dollars, Australian dollars, or rupees, we converted them into approximate USD equivalents for consistency.

Sometimes different sources report slightly different numbers, or the exact round size is not fully disclosed. In those cases, we flag the uncertainty and assign a confidence label to each startup, visible in the last column.

Here is what they mean.

Full confidence: The longevity startup's equity fundraising history can be reconstructed completely from public sources. The rounds, dates, amounts, and key investors are clearly identified, with no meaningful gaps.

Strong confidence: The fundraising history is largely complete and reliable. There may be a small missing detail, such as incomplete investor information or a minor round with limited data, but the overall record is clear.

Partial confidence: The main fundraising rounds can be identified, but the record is incomplete or somewhat mixed. Some rounds may be missing or certain funding events may be difficult to separate clearly.

Low confidence: Public information is too limited, inconsistent, or ambiguous to reliably reconstruct the company's equity fundraising history.

When the confidence level is too low, we take a conservative approach and exclude the company from the ranking. We don't want to include data that cannot be reliably verified.

This reflects how we conduct all our research, including the work behind our report covering the longevity market.

In a world where LLMs hallucinate and unreliable information is everywhere, our goal is simple: provide data you can trust.

If you want the full detail on a specific calculation, feel free to contact us and we will gladly explain.

Finally, know that we update the dataset once per month, so come back here if you need fresh information.

chart function health longevity market

In our longevity market deck, we identify repeatable patterns you can use if you’re building in this market

Who is the author of this content?

NEW MARKET PITCH TEAM

We track new markets so founders and investors can move faster

We build living “market pitch” documents for emerging markets: from AI to synthetic biology and new proteins. Instead of digging through outdated PDFs, random blog posts, and hallucinated LLM answers, our clients get a clean, visual, always-updated view of what’s really happening. We map the key players, deals, regulations, metrics and signals that matter so you can decide faster whether a market is worth your time. Want to know more? Check out our about page.

How we created this content 🔎📝

At New Market Pitch, we kept seeing the same problem: when you look at a new market, the data is either missing, paywalled, or buried in 300-page reports that feel like they were written in the 80s. On the other side, LLMs and random blog posts give you confident answers with no sources, and sometimes they just make things up. That’s not good enough when you’re about to invest real money or launch a company.

So we decided to fix the experience. For each market we cover, we build a structured database and update it on a regular basis. We track funding rounds, fund memos, M&A moves, partnerships, new products, policy changes, and the real activity of startups and incumbents. Then we turn all of that into a clear “market pitch” that shows where the opportunities are and how people actually win in that space.

Every key data point is checked, sourced, and put back into context by our team. That’s how we can give you both speed and reliability: fast coverage of new markets, without the usual guesswork.

Back to blog